Dieter Dauwe1, Beatriz Pelacho2, Arief Wibowo3, Ann-Sophie Walravens3, Kristoff Verdonck4, Hilde Gillijns3, Ellen Caluwe3, Peter Pokreisz3, Nick van Gastel5, Geert Carmeliet5, Maarten Depypere6, Frederik Maes6, Nina Vanden Driessche3, Walter Droogne3, Johan Van Cleemput3, Johan Vanhaecke3, Felipe Prosper7, Catherine Verfaillie8, Aernout Luttun4, Stefan Janssens1. 1. Department of Cardiovascular Sciences, Clinical Cardiology, KU Leuven, Leuven, Belgium dieter.dauwe@med.kuleuven.be stefan.janssens@med.kuleuven.be. 2. Cell Therapy Department, Center for Applied Medicine Research, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain. 3. Department of Cardiovascular Sciences, Clinical Cardiology, KU Leuven, Leuven, Belgium. 4. Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium. 5. Department of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium. 6. Department of Electrical Engineering, Center for the Processing of Speech and Images, KU Leuven, Leuven, Belgium. 7. Cell Therapy Department, Center for Applied Medicine Research, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain Hematology Department, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain. 8. Department of Development and Regeneration, Stem Cell Biology and Embryology, KU Leuven, Leuven, Belgium.
Abstract
BACKGROUND: Blood outgrowth endothelial cells (BOECs) mediate therapeutic neovascularization in experimental models, but outgrowth characteristics and functionality of BOECs from patients with ischemic cardiomyopathy (ICMP) are unknown. We compared outgrowth efficiency and in vitro and in vivo functionality of BOECs derived from ICMP with BOECs from age-matched (ACON) and healthy young (CON) controls. METHODS AND RESULTS: We isolated 3.6±0.6 BOEC colonies/100×10(6) mononuclear cells (MNCs) from 60-mL blood samples of ICMP patients (n=45; age: 66±1 years; LVEF: 31±2%) versus 3.5±0.9 colonies/100×10(6) MNCs in ACON (n=32; age: 60±1 years) and 2.6±0.4 colonies/100×10(6) MNCs in CON (n=55; age: 34±1 years), P=0.29. Endothelial lineage (VEGFR2(+)/CD31(+)/CD146(+)) and progenitor (CD34(+)/CD133(-)) marker expression was comparable in ICMP and CON. Growth kinetics were similar between groups (P=0.38) and not affected by left ventricular systolic dysfunction, maladaptive remodeling, or presence of cardiovascular risk factors in ICMP patients. In vitro neovascularization potential, assessed by network remodeling on Matrigel and three-dimensional spheroid sprouting, did not differ in ICMP from (A)CON. Secretome analysis showed a marked proangiogenic profile, with highest release of angiopoietin-2 (1.4±0.3×10(5) pg/10(6) ICMP-BOECs) and placental growth factor (5.8±1.5×10(3) pg/10(6) ICMP BOECs), independent of age or ischemic disease. Senescence-associated β-galactosidase staining showed comparable senescence in BOECs from ICMP (5.8±2.1%; n=17), ACON (3.9±1.1%; n=7), and CON (9.0±2.8%; n=13), P=0.19. High-resolution microcomputed tomography analysis in the ischemic hindlimb of nude mice confirmed increased arteriogenesis in the thigh region after intramuscular injections of BOECs from ICMP (P=0.025; n=8) and CON (P=0.048; n=5) over vehicle control (n=8), both to a similar extent (P=0.831). CONCLUSIONS: BOECs can be successfully culture-expanded from patients with ICMP. In contrast to impaired functionality of ICMP-derived bone marrow MNCs, BOECs retain a robust proangiogenic profile, both in vitro and in vivo, with therapeutic potential for targeting ischemic disease.
BACKGROUND: Blood outgrowth endothelial cells (BOECs) mediate therapeutic neovascularization in experimental models, but outgrowth characteristics and functionality of BOECs from patients with ischemic cardiomyopathy (ICMP) are unknown. We compared outgrowth efficiency and in vitro and in vivo functionality of BOECs derived from ICMP with BOECs from age-matched (ACON) and healthy young (CON) controls. METHODS AND RESULTS: We isolated 3.6±0.6 BOEC colonies/100×10(6) mononuclear cells (MNCs) from 60-mL blood samples of ICMPpatients (n=45; age: 66±1 years; LVEF: 31±2%) versus 3.5±0.9 colonies/100×10(6) MNCs in ACON (n=32; age: 60±1 years) and 2.6±0.4 colonies/100×10(6) MNCs in CON (n=55; age: 34±1 years), P=0.29. Endothelial lineage (VEGFR2(+)/CD31(+)/CD146(+)) and progenitor (CD34(+)/CD133(-)) marker expression was comparable in ICMP and CON. Growth kinetics were similar between groups (P=0.38) and not affected by left ventricular systolic dysfunction, maladaptive remodeling, or presence of cardiovascular risk factors in ICMPpatients. In vitro neovascularization potential, assessed by network remodeling on Matrigel and three-dimensional spheroid sprouting, did not differ in ICMP from (A)CON. Secretome analysis showed a marked proangiogenic profile, with highest release of angiopoietin-2 (1.4±0.3×10(5) pg/10(6) ICMP-BOECs) and placental growth factor (5.8±1.5×10(3) pg/10(6) ICMP BOECs), independent of age or ischemic disease. Senescence-associated β-galactosidase staining showed comparable senescence in BOECs from ICMP (5.8±2.1%; n=17), ACON (3.9±1.1%; n=7), and CON (9.0±2.8%; n=13), P=0.19. High-resolution microcomputed tomography analysis in the ischemic hindlimb of nude mice confirmed increased arteriogenesis in the thigh region after intramuscular injections of BOECs from ICMP (P=0.025; n=8) and CON (P=0.048; n=5) over vehicle control (n=8), both to a similar extent (P=0.831). CONCLUSIONS: BOECs can be successfully culture-expanded from patients with ICMP. In contrast to impaired functionality of ICMP-derived bone marrow MNCs, BOECs retain a robust proangiogenic profile, both in vitro and in vivo, with therapeutic potential for targeting ischemic disease.
Authors: Zhi Chen; Sandra M S Herrmann; Xiangyang Zhu; Kyra L Jordan; Monika L Gloviczki; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Hypertension Date: 2014-07-21 Impact factor: 10.190
Authors: Frederic Pipp; Matthias Heil; Katja Issbrücker; Tibor Ziegelhoeffer; Sandra Martin; Joop van den Heuvel; Herbert Weich; Borja Fernandez; Gershon Golomb; Peter Carmeliet; Wolfgang Schaper; Matthias Clauss Journal: Circ Res Date: 2003-01-23 Impact factor: 17.367
Authors: Aernout Luttun; Marc Tjwa; Lieve Moons; Yan Wu; Anne Angelillo-Scherrer; Fang Liao; Janice A Nagy; Andrea Hooper; Josef Priller; Bert De Klerck; Veerle Compernolle; Evis Daci; Peter Bohlen; Mieke Dewerchin; Jean-Marc Herbert; Roy Fava; Patrick Matthys; Geert Carmeliet; Désiré Collen; Harold F Dvorak; Daniel J Hicklin; Peter Carmeliet Journal: Nat Med Date: 2002-07-01 Impact factor: 53.440
Authors: K Tobler; A Freudenthaler; S M Baumgartner-Parzer; M Wolzt; B Ludvik; E Nansalmaa; P J Nowotny; D Seidinger; S Steiner; A Luger; M Artwohl Journal: Int J Obes (Lond) Date: 2010-01-12 Impact factor: 5.095
Authors: John D Stroncek; Bryan S Grant; Melissa A Brown; Thomas J Povsic; George A Truskey; William M Reichert Journal: Tissue Eng Part A Date: 2009-11 Impact factor: 3.845
Authors: Marta Rojas-Torres; Ismael Sánchez-Gomar; Antonio Rosal-Vela; Lucía Beltrán-Camacho; Sara Eslava-Alcón; José Ángel Alonso-Piñeiro; Javier Martín-Ramírez; Rafael Moreno-Luna; Mª Carmen Durán-Ruiz Journal: Stem Cell Res Ther Date: 2022-06-21 Impact factor: 8.079
Authors: Dieter Dauwe; Beatriz Pelacho; Arief Wibowo; Ann-Sophie Walravens; Kristoff Verdonck; Hilde Gillijns; Ellen Caluwe; Peter Pokreisz; Nick van Gastel; Geert Carmeliet; Maarten Depypere; Frederik Maes; Nina Vanden Driessche; Walter Droogne; Johan Van Cleemput; Johan Vanhaecke; Felipe Prosper; Catherine Verfaillie; Aernout Luttun; Stefan Janssens Journal: J Am Heart Assoc Date: 2016-04-18 Impact factor: 5.501
Authors: Vera van de Pol; Lidia R Bons; Kirsten Lodder; Konda Babu Kurakula; Gonzalo Sanchez-Duffhues; Hans-Marc J Siebelink; Jolien W Roos-Hesselink; Marco C DeRuiter; Marie-José Goumans Journal: Int J Mol Sci Date: 2019-07-02 Impact factor: 5.923